

Breast Cancer

Stage zero ductal carcinoma
in situ

Do you really need
radiation for your
DCIS?



oncotype dx[®]
Breast DCIS Score

by EXACT SCIENCES

Why Did My Doctor Order This Test?

When it comes to treatment decisions for your stage zero ductal carcinoma in situ breast cancer (DCIS), you have a few treatment options.

Many patients choose to have a lumpectomy. Doctors frequently recommend radiation therapy after this surgery to reduce the chance of your DCIS coming back. But radiation can have side effects and life-changing complications. The Oncotype DX Breast DCIS Score[®] test can help you and your doctor identify the risk of your cancer coming back and design a personalized treatment plan based on the biology of your tumor.

Genomic Testing – The Key to Knowing Your Cancer

Unlike a genetic test which assesses your hereditary risk for cancer, a genomic test analyzes cancer tissue to provide information on how a tumor might behave. It identifies changes in DNA that may be driving the growth of your tumor. The DCIS Score[®] test examines specific genes found inside your DCIS to determine the aggressiveness of the individual tumor and can predict the risk of a recurrence of either DCIS or invasive breast cancer.

Pioneering Research

In a large study,¹ the Oncotype DX Breast DCIS Score test showed that 70% of women are at low risk for recurrence and may be able to forego radiation therapy. The Oncotype DX Breast DCIS Score test can help women and their doctors confidently choose the most appropriate treatment, helping many patients avoid the consequences and cost of unneeded radiation therapy, while identifying those who need more aggressive treatment.

What Can I Expect from My Test Results?


Your results are reported as a Breast DCIS Score result based on a scale of 0-100. This unique score, refined by your age and your tumor size, indicates how likely your DCIS is to return in the same breast during the next 10 years as either DCIS or invasive breast cancer following your lumpectomy. The lower your score, the lower the likelihood your cancer will come back in that breast. Your DCIS Score report also includes the expression of the estrogen and progesterone receptors in your DCIS so you can make informed hormone therapy decisions. Make sure to review your test results with your doctor.

How likely is it that my DCIS will come back?


Your test result can indicate the likelihood that your DCIS will recur as DCIS or invasive breast cancer within the next 10 years.

Based on my score, do I need radiation therapy?

Probably not. 92 out of 100 women with a score of 5 would not see a recurrence of DCIS or invasive cancer within 10 years.

Breast DCIS Score Report


Patient Educational Summary
What does your result mean?




5

Your Breast DCIS Score result of 5, combined with information about your age and tumor size, indicates a **8%** risk of your tumor returning as DCIS or invasive cancer in the same breast within 10 years, if treated only with breast-conserving surgery.

By measuring the activity of certain genes in your breast tumor tissue, the Oncotype DX[®] test predicts the risk of disease returning in the same breast, as either DCIS or invasive cancer - a key factor in deciding your treatment following DCIS surgery.

What are the chances of your breast cancer returning?





If 100 women with a Breast DCIS Score result of **5** are treated with only breast-conserving surgery:


92 women will **not** have their disease return in the same breast as either DCIS or invasive cancer within 10 years.


8 women will have their disease return in the same breast as either DCIS or invasive cancer within 10 years. 4 women will have their disease return in the same breast as invasive cancer within 10 years.

What are your treatment options? (For doctor/patient discussion)

 SURGERY

 RADIATION

 ENDOCRINE THERAPY




 MONITORING

CDX-8001 Rev009 Page 3 of 3

© 2004-2017 Genomic Health, Inc. All rights reserved. Genomic Health, Oncotype DX, and Breast DCIS Score are trademarks of Genomic Health, Inc.

Over 1 million breast cancer patients have used an Oncotype DX[®] test to help guide their treatment decisions.²

How does it work?

	<p>1. The tissue from your most recent biopsy or lumpectomy is sent to our lab for analysis. No additional procedures are required.</p>
	<p>2. Test results are sent to your doctor.</p>
	<p>3. You and your doctor review the results together.</p>



If you would like to share your story with other patients about your experience with the Oncotype DX DCIS Score[®] test, please contact us at:
patientstories@exactsciences.com

Learn More About Your Insurance Options

Patients have **\$0 financial responsibility** for DCIS Score test when Medicare fee-for-service (FFS) coverage criteria are met.

Medicare Advantage, which is provided by commercial insurance companies, may have different financial responsibility compared to Medicare FFS.

To learn about Medicare coverage, private insurance coverage, and other financial options, contact our Customer Service group by phone at:

888-ONCOTYPE (888-662-6897)

– **select option 2**

or by email at:

oncotype@exactsciences.com



Scan here or visit:
ExactSciencesPO.com for
more information.

EXACT SCIENCES

Oncotype DX, Oncotype DX Breast DCIS Score, and DCIS Score are registered trademarks of Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences Corporation. Exact Sciences is a registered trademark of Exact Sciences Corporation. © 2022 Genomic Health, Inc. All rights reserved. M-US-DCIS-00058_0424

This educational piece is not designed to provide individual advice in connection with your diagnosis or treatment plan. Talk to your health care provider about such matters and whether the Oncotype DX DCIS Score test may be right for you. Individual results may vary.